REDWOOD CITY, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Sunil Patel, Chief Financial Officer, Senior Vice President, Corporate Development and Finance, will speak at the 26th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 pm Eastern Time.
The presentation will be webcast live and available for replay from the OncoMed website in the Investor Relations section.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, an Investigational New Drug (IND) application has been accepted for OncoMed's anti-DLL4/anti-VEGF bispecific antibody (OMP-305B83) and the company plans to file an IND application for anti-RSPO3 (OMP-131R10) in early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
CONTACT: OncoMed Pharmaceuticals Michelle Corral Investor Relations and Corporate Communications firstname.lastname@example.org (650) 995-8373 Shari Annes Annes Associates email@example.com (650) 888-0902
Source:OncoMed Pharmaceuticals, Inc.